Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Payables: 2011-2025

Historic Payables for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to $8.2 million.

  • Lifecore Biomedical's Payables fell 49.68% to $8.2 million in Q2 2025 from the same period last year, while for May 2025 it was $48.6 million, marking a year-over-year decrease of 27.17%. This contributed to the annual value of $8.2 million for FY2025, which is 49.68% down from last year.
  • Lifecore Biomedical's Payables amounted to $8.2 million in Q2 2025, which was up 11.01% from $7.4 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical's Payables peaked at $22.1 million during Q2 2023, and registered a low of $7.4 million during Q1 2025.
  • In the last 3 years, Lifecore Biomedical's Payables had a median value of $15.7 million in 2023 and averaged $15.2 million.
  • In the last 5 years, Lifecore Biomedical's Payables tumbled by 86.04% in 2021 and then surged by 70.61% in 2023.
  • Over the past 5 years, Lifecore Biomedical's Payables (Quarterly) stood at $8.7 million in 2021, then soared by 53.68% to $13.3 million in 2022, then surged by 43.02% to $19.0 million in 2023, then fell by 21.32% to $15.0 million in 2024, then crashed by 49.68% to $8.2 million in 2025.
  • Its Payables was $8.2 million in Q2 2025, compared to $7.4 million in Q1 2025 and $15.0 million in Q4 2024.